HepB mAb19(Rockefeller University)

N/A

Report date: 2025/03/19 16:06:41

Base Information

Drug NameHepB mAb19(Rockefeller University)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-HBsAg
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmark
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Rockefeller UniversityNyu Langone Health
China Registration ClassN/A

Develop Information

Active CompaniesCharite University, Berlin, GermanyNyu Langone HealthThe Rockefeller University
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A